JP2014506900A5 - - Google Patents

Download PDF

Info

Publication number
JP2014506900A5
JP2014506900A5 JP2013555798A JP2013555798A JP2014506900A5 JP 2014506900 A5 JP2014506900 A5 JP 2014506900A5 JP 2013555798 A JP2013555798 A JP 2013555798A JP 2013555798 A JP2013555798 A JP 2013555798A JP 2014506900 A5 JP2014506900 A5 JP 2014506900A5
Authority
JP
Japan
Prior art keywords
solution
tapentadol
criteria
hcl
result
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013555798A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014506900A (ja
JP6027549B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/000906 external-priority patent/WO2012119729A1/en
Publication of JP2014506900A publication Critical patent/JP2014506900A/ja
Publication of JP2014506900A5 publication Critical patent/JP2014506900A5/ja
Application granted granted Critical
Publication of JP6027549B2 publication Critical patent/JP6027549B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013555798A 2011-03-04 2012-03-02 タペンタドールを含む半固形の水性医薬組成物 Expired - Fee Related JP6027549B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161449329P 2011-03-04 2011-03-04
US61/449,329 2011-03-04
EP11003603 2011-05-03
EP11003603.5 2011-05-03
PCT/EP2012/000906 WO2012119729A1 (en) 2011-03-04 2012-03-02 Semisolid aqueous pharmaceutical composition containing tapentadol

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016200663A Division JP6259042B2 (ja) 2011-03-04 2016-10-12 タペンタドールを含む半固形の水性医薬組成物

Publications (3)

Publication Number Publication Date
JP2014506900A JP2014506900A (ja) 2014-03-20
JP2014506900A5 true JP2014506900A5 (enExample) 2016-09-01
JP6027549B2 JP6027549B2 (ja) 2016-11-16

Family

ID=44652117

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2013555798A Expired - Fee Related JP6027549B2 (ja) 2011-03-04 2012-03-02 タペンタドールを含む半固形の水性医薬組成物
JP2016200663A Expired - Fee Related JP6259042B2 (ja) 2011-03-04 2016-10-12 タペンタドールを含む半固形の水性医薬組成物
JP2017228602A Expired - Fee Related JP6670283B2 (ja) 2011-03-04 2017-11-29 タペンタドールを含む半固形の水性医薬組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016200663A Expired - Fee Related JP6259042B2 (ja) 2011-03-04 2016-10-12 タペンタドールを含む半固形の水性医薬組成物
JP2017228602A Expired - Fee Related JP6670283B2 (ja) 2011-03-04 2017-11-29 タペンタドールを含む半固形の水性医薬組成物

Country Status (24)

Country Link
US (3) US9446008B2 (enExample)
EP (3) EP3766489B1 (enExample)
JP (3) JP6027549B2 (enExample)
KR (2) KR102039320B1 (enExample)
CN (1) CN103501774A (enExample)
AU (2) AU2012224954C1 (enExample)
BR (1) BR112013022556A8 (enExample)
CA (1) CA2828637C (enExample)
CY (1) CY1119725T1 (enExample)
DK (1) DK2680834T3 (enExample)
EA (2) EA033171B1 (enExample)
ES (2) ES2910085T3 (enExample)
HR (1) HRP20171836T1 (enExample)
HU (1) HUE037491T2 (enExample)
IL (2) IL227826B (enExample)
LT (1) LT2680834T (enExample)
MX (2) MX374468B (enExample)
NO (1) NO2680834T3 (enExample)
PL (1) PL2680834T3 (enExample)
PT (2) PT3766489T (enExample)
RS (1) RS56692B1 (enExample)
SI (1) SI2680834T1 (enExample)
WO (1) WO2012119729A1 (enExample)
ZA (1) ZA201306480B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3685827A1 (en) 2011-03-04 2020-07-29 Grünenthal GmbH Aqueous pharmaceutical formulation of tapentadol for oral administration
PT3766489T (pt) 2011-05-03 2022-04-07 Gruenenthal Gmbh Composição farmacêutica aquosa semissólida contendo tapentadol
US8997860B2 (en) 2011-08-05 2015-04-07 Halliburton Energy Services, Inc. Methods for monitoring the formation and transport of a fracturing fluid using opticoanalytical devices
US9395306B2 (en) 2011-08-05 2016-07-19 Halliburton Energy Services, Inc. Methods for monitoring fluids within or produced from a subterranean formation during acidizing operations using opticoanalytical devices
US9228940B2 (en) 2012-09-14 2016-01-05 Halliburton Energy Services, Inc. Systems, methods, and apparatuses for in situ monitoring of cement fluid compositions and setting processes thereof
US8619256B1 (en) 2012-09-14 2013-12-31 Halliburton Energy Services, Inc. Systems and methods for monitoring the properties of a fluid cement composition in a flow path
US20140076550A1 (en) 2012-09-14 2014-03-20 Halliburton Energy Services, Inc. Systems and Methods for Detecting Microannulus Formation and Remediation
EP3027214A1 (en) * 2013-08-02 2016-06-08 ratiopharm GmbH Composition comprising tapentadol in a dissolved form
EP2845625A1 (en) 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
JP6923447B2 (ja) * 2015-03-27 2021-08-18 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング タペンタドールの非経口投与のための安定な製剤
EP3515412B1 (en) 2016-09-23 2025-04-23 Grünenthal GmbH Stable formulation for parenteral administration of tapentadol
WO2020020879A1 (en) * 2018-07-24 2020-01-30 Dr. August Wolff Gmbh & Co. Kg Arzneimittel Topical emulsion of an anticholinergic compound
KR102928295B1 (ko) 2018-09-07 2026-02-13 알.피.쉐러 테크놀러지즈 엘엘씨 경화 및 낮은 hlb 계면 활성제(들)의 첨가를 통한 고체 또는 반고체 지질 기반 제형 안정화
US12447119B2 (en) 2019-03-18 2025-10-21 Sunstar Americas, Inc. Oral care composition

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775678A (en) * 1984-10-01 1988-10-04 Schering Corporation Clotrimazole cream
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
US6183758B1 (en) * 1998-01-29 2001-02-06 Highland Laboratories, Inc. Phytochemicals, nutrients & medication absorption &/or treatment
US6399087B1 (en) 2000-12-20 2002-06-04 Amphastar Pharmaceuticals, Inc. Propofol formulation with enhanced microbial inhibition
US20050176790A1 (en) * 2001-02-28 2005-08-11 Johannes Bartholomaus Pharmaceutical salts
DE10109763A1 (de) 2001-02-28 2002-09-05 Gruenenthal Gmbh Pharmazeutische Salze
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
PT1485078E (pt) 2002-03-15 2013-01-14 Cypress Bioscience Inc Milnacipran para o tratamento do síndrome do intestino irritável
US20030191187A1 (en) 2002-04-01 2003-10-09 Lee Fang Yu Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same
MXPA05002728A (es) 2002-09-13 2005-07-25 Cydex Inc Capsulas que contienen composiciones de relleno acuoso estabilizadas con ciclodextrina derivada.
US20040180915A1 (en) 2003-03-14 2004-09-16 Xanodyne Pharmacal, Inc. Methadone-containing compositions for parenteral administration and method of use thereof
WO2005112926A1 (en) 2004-05-17 2005-12-01 Pharmacofore, Inc. Compositions and methods for treating or preventing pain
ES2291780T3 (es) 2004-06-28 2008-03-01 Grunenthal Gmbh Formas cristalinas del clorhidrato de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)fenol.
AR053304A1 (es) 2004-07-01 2007-05-02 Gruenenthal Gmbh Formas farmaceuticas orales protegidas frente al abuso con liberacion controlada de (1r,2r)-3-(3 dimetilamino-1-etil-2metil-propil)fenol y procedimiento para su produccion.
CA2606947A1 (en) 2005-04-28 2006-11-02 Theraquest Biosciences Llc Methods and compositions for treating pain
TWI329334B (en) 2005-12-02 2010-08-21 Chung Shan Inst Of Science Manufacture method of electromagnetic interference layer for the plasma display panel
US20080039405A1 (en) * 2006-04-25 2008-02-14 Croda, Inc. Modification of percutaneous absorption of topically active materials
CN102675136B (zh) 2006-04-28 2016-01-20 格吕伦塔尔有限公司 包含3-(3-二甲基氨基-1-乙基-2-甲基-丙基)-苯酚和nsaid的药物组合物
CN101431990B (zh) 2006-04-28 2011-08-03 格吕伦塔尔有限公司 包含3-(3-二甲基氨基-1-乙基-2-甲基-丙基)-酚和对乙酰氨基酚的药物结合
SI2046726T1 (sl) 2006-07-24 2010-05-31 Janssen Pharmaceutica Nv Priprava R R metoksifenil N N trimetilpentanamina
DE102007012165A1 (de) 2007-03-12 2008-09-18 Grünenthal GmbH Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie des Neuropathieschmerzes
EP1985292A1 (en) 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
MX2010005680A (es) 2007-11-23 2010-12-21 Protect Pharmaceutical Corp Composiciones de tapentadol.
TWI454288B (zh) 2008-01-25 2014-10-01 Gruenenthal Chemie 藥物劑型
SI2352494T1 (sl) 2008-10-30 2019-12-31 Gruenenthal Gmbh Nove in potentne dozirne oblike tapentadola
WO2010100477A2 (en) 2009-03-03 2010-09-10 Shire Llc Amino acid and peptide carbamate prodrugs of tapentadol and uses thereof
US20100272815A1 (en) 2009-04-28 2010-10-28 Actavis Group Ptc Ehf Amorphous form of tapentadol hydrochloride
WO2011083304A1 (en) * 2010-01-05 2011-07-14 Shire Llc Prodrugs of opioids and uses thereof
CA2794734C (en) * 2010-03-30 2017-12-12 Phosphagenics Limited Transdermal delivery patch
GB201006200D0 (en) 2010-04-14 2010-06-02 Ayanda As Composition
US20120270848A1 (en) * 2010-10-22 2012-10-25 Galleon Pharmaceuticals, Inc. Novel Compositions and Therapeutic Methods Using Same
PT3766489T (pt) * 2011-05-03 2022-04-07 Gruenenthal Gmbh Composição farmacêutica aquosa semissólida contendo tapentadol

Similar Documents

Publication Publication Date Title
NZ712270A (en) Pharmaceutical composition of s-ketamine hydrochloride
MY179756A (en) Stabilized efinaconazole formulations
PE20140591A1 (es) Uso de una composicion que comprende un peptido antimicrobiano como un conservador de alimentos
RU2015141767A (ru) Композиции и способы для местной доставки простагландинов в подкожный жир
WO2015085070A3 (en) Liquid-fertilized ready formulations of bifenthrin
WO2014182566A3 (en) Preservation system for nutritional substances
CN108026053A8 (zh) 作为mIDH1抑制剂的稠合的咪唑类化合物
WO2016142224A8 (en) Fungicidal mixtures comprising strobilurin-type fungicides
WO2015171460A3 (en) Formulations of cyclophosphamide liquid concentrate
WO2015003082A3 (en) Volatile organic compound formulations having antimicrobial activity
WO2015198265A3 (en) Disinfectant and antimicrobial compositions, in particular for the veterinary field
EP2692723A8 (en) Aryloxy dihalopropenyl ether compound and use thereof
MX2016000136A (es) Mezclas conservantes sinergicas.
WO2014169003A3 (en) Multi-functional composition for cosmetic formulations
EA201792144A1 (ru) Стабильный препарат для парентерального введения тапентадола
WO2017069820A3 (en) Antimicrobial composition having efficacy against endospores
WO2012131117A8 (es) Utilización de antifúngicos naturales para prevenir la infección de lesiones, injertos y heridas de poda en plantas leñosas por hongos fitopatógenos
JP2017531030A5 (enExample)
MX2015011118A (es) Extracto de cafe que contiene acido protocatecuico y su uso en agroquimica contra patogenos de plantas.
RU2010146997A (ru) Фармацевтическая композиция, содержащая силденафил и/или алпростадил, миноксидил и/или эуфиллин, тестостерон и/или йохимбин и липосомы для местного применения
PH12013502250A1 (en) Construction material preservative
CN105682672A8 (zh) 含有来自毛泡桐的香叶基黄酮作为有效成分的用于抑制神经氨酸酶活性的组合物
JP2018070453A5 (enExample)
WO2012169860A3 (ko) 콩 추출물을 포함하는 탈모 방지 또는 육모 촉진용 조성물
WO2014137231A3 (en) Totarol extract formulations and uses thereof